Kindall G. Jackson

Cooley advised the underwriters in Merus’ $172.5 million follow-on offering. Jefferies, BofA Securities, Guggenheim Securities and William Blair acted as joint book-running managers for the offering. Merus is a clinical-stage oncology company developing innovative, full-length human bispecific and trispecific antibody therapeutics, referred to as Multiclonics. Partners Denny Won, Courtney Thorne and Div Gupta led the Cooley team.

Cooley advised CinCor Pharma, a clinical-stage biopharmaceutical company, on its definitive agreement to be acquired by AstraZeneca. M&A partners Rama Padmanabhan and Rowook Park and corporate partners Div Gupta and Sarah Sellers led the Cooley team.

Cooley advised the underwriters in Cerevel Therapeutics’ $253.8 million follow-on offering of 7,250,000 shares of its common stock at a public offering price of $35 per share and the initial purchasers in its $345.0 million Rule 144A convertible notes offering. Cerevel is a clinical-stage biopharmaceutical company pursuing a targeted approach to neuroscience that combines a deep understanding of disease-related biology and neurocircuitry of the brain with advanced chemistry and central nervous system target receptor selective pharmacology to discover and design new therapies. Lawyers Div Gupta, Daniel Goldberg, Eric Blanchard, Mischi a Marca, Jason Savich, Minkyu Park, Amiti Rothstein, Ellie Guadiana, Matt Kong, Eric Delgado and Jordan Verrilli led the Cooley team.

Cooley advised the underwriters in Verona Pharma’s $150 million follow-on offering of 14,260,000 American depositary shares at a public offering price of $10.50 per American depositary share. Verona is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapeutics for the treatment of respiratory diseases with significant unmet medical needs. Lawyers Daniel Goldberg, Eric Blanchard, Div Gupta, Charlie Kim, Minkyu Park, Amiti Rothstein and Olivia Creser led the Cooley team.

Cooley advised the underwriters in Verve Therapeutics’ $258.8 million follow-on offering of 9,583,334 shares of common stock at a public offering price of $27 per share. Verve is a genetic medicines company pioneering a new approach to the care of cardiovascular disease, potentially transforming treatment from chronic management to single-course gene-editing medicines. Partners Rich Segal and Div Gupta, and associate Darah Protas, led the Cooley team.